Innovative therapeutic modalities in oncology are advancing rapidly. BioNTech and DualityBio reported a Phase 3 interim breast cancer ADC success, demonstrating improved progression-free survival in HER2-positive patients. Radiance Biopharma secured global rights in a $1.165 billion deal for a bispecific nanobody ADC targeting c-MET and EGFR in solid tumors. Oncolytic viruses combined with immunotherapy are producing synergistic anti-tumor effects in preclinical rodent solid tumor models, heralding a new era in cancer treatment. Additionally, novel immune checkpoint inhibitors targeting innate immune pathways have shown efficacy, broadening the spectrum of immunotherapeutic strategies.